Terns Pharmaceuticals, Inc. (TERN)
NASDAQ: TERN · Real-Time Price · USD
5.60
-0.31 (-5.25%)
At close: Nov 20, 2024, 4:00 PM
5.72
+0.12 (2.14%)
After-hours: Nov 20, 2024, 6:44 PM EST

Terns Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018
Revenue
---1--
Upgrade
Gross Profit
---1--
Upgrade
Selling, General & Admin
30.4139.0622.4119.5598.66
Upgrade
Research & Development
69.5763.539.6231.3128.0326.53
Upgrade
Operating Expenses
99.98102.5662.0350.8637.0335.2
Upgrade
Operating Income
-99.98-102.56-62.03-49.86-37.03-35.2
Upgrade
Interest & Investment Income
12.4812.92.110.170.061.2
Upgrade
Other Non Operating Income (Expenses)
-0.3-0.31-0.070.040.10.15
Upgrade
EBT Excluding Unusual Items
-87.8-89.97-59.99-49.65-36.87-33.84
Upgrade
Other Unusual Items
----7.81-35
Upgrade
Pretax Income
-87.8-89.97-59.99-49.65-29.06-68.84
Upgrade
Income Tax Expense
0.270.240.360.510.81-0.02
Upgrade
Earnings From Continuing Operations
-88.07-90.21-60.35-50.16-29.87-68.82
Upgrade
Minority Interest in Earnings
----0.520.21
Upgrade
Net Income
-88.07-90.21-60.35-50.16-29.35-68.61
Upgrade
Net Income to Common
-88.07-90.21-60.35-50.16-29.35-68.61
Upgrade
Shares Outstanding (Basic)
7571362300
Upgrade
Shares Outstanding (Diluted)
7571362300
Upgrade
Shares Change (YoY)
11.75%97.76%58.69%7862.47%55.60%145.81%
Upgrade
EPS (Basic)
-1.18-1.27-1.67-2.21-102.93-374.39
Upgrade
EPS (Diluted)
-1.18-1.27-1.67-2.21-102.93-374.39
Upgrade
Free Cash Flow
-74.83-67.44-49.38-42.17-30.39-67.12
Upgrade
Free Cash Flow Per Share
-1.00-0.95-1.37-1.86-106.58-366.26
Upgrade
Gross Margin
---100.00%--
Upgrade
Operating Margin
----4986.00%--
Upgrade
Profit Margin
----5015.80%--
Upgrade
Free Cash Flow Margin
----4216.70%--
Upgrade
EBITDA
-99.66-102.27-61.55-49.35-36.63-35
Upgrade
D&A For EBITDA
0.330.290.480.510.390.2
Upgrade
EBIT
-99.98-102.56-62.03-49.86-37.03-35.2
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.